Clinical Trials Logo

Clinical Trial Summary

Epidemiological evidence is accumulating that a high consumption of added sugars is associated with metabolic diseases such as non-alcoholic fatty liver disease and type 2 diabetes. Fructose, one of the principal added sugars, is believed to be the most disadvantageous sugar. Data from a large population-based cohort demonstrated that fructose intake from fruit juice and sugar-sweetened beverages, but not whole fruits, is associated with higher intrahepatic lipid content. A study in mice demonstrated that fast fructose exposure resulted in higher intrahepatic lipid content than slow fructose exposure. The food matrix, i.e. the complex spatial organisation of and interactions between nutrients, may account for the fast versus slow fructose exposure and subsequent health consequences. Therefore the investigators aim to investigate the role of the fructose matrices on serum fructose peaks. The investigators hypothesize that liquid fructose matrices will cause higher serum fructose peaks in comparison to solid fructose matrices. Objective: To quantify serum fructose peaks within 150 minutes following intake of fructose-containing matrices.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT05826717
Study type Interventional
Source Maastricht University Medical Center
Contact
Status Active, not recruiting
Phase N/A
Start date December 15, 2022
Completion date December 2023

See also
  Status Clinical Trial Phase
Completed NCT03939130 - Fructose Rich Diet and Endothelial Function N/A
Active, not recruiting NCT03352596 - Low Fructose Diet in Diabetes Type 2 N/A